Similar articles

• New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions.

  Pantuck AJ, Zisman A, Henderson D, Wilson D, Schreiber A, Belldegrun A. Pantuck AJ, et al. Urology. 2001 Apr;57(4 Suppl 1):95-9. doi: 10.1016/s0090-4295(00)00950-x. Urology. 2001. PMID: 11295604 Review.
• Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL-2): a phase I study.

  Sobol RE, Royston I, Fakhrai H, Shawler DL, Carson C, Dorigo O, Gjerset R, Gold DP, Koziol J, Mercola D, et al. Sobol RE, et al. Hum Gene Ther. 1995 Feb;6(2):195-204. doi: 10.1089/hum.1995.6.2-195. Hum Gene Ther. 1995. PMID: 7734519 No abstract available.
• Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.

  Belldegrun A, Tso CL, Zisman A, Naitoh J, Said J, Pantuck AJ, Hinkel A, deKernion J, Figlin R. Belldegrun A, et al. Hum Gene Ther. 2001 May 20;12(8):883-92. doi: 10.1089/104303401750195854. Hum Gene Ther. 2001. PMID: 11387054 Clinical Trial.
• A phase I trial of adenovector-mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer.

  Trudel S, Trachtenberg J, Toi A, Sweet J, Li ZH, Jewett M, Tshilias J, Zhuang LH, Hitt M, Wan Y, Gauldie J, Graham FL, Dancey J, Stewart AK. Trudel S, et al. Cancer Gene Ther. 2003 Oct;10(10):755-63. doi: 10.1038/sj.cgt.7700626. Cancer Gene Ther. 2003. PMID: 14502228 Clinical Trial.
• Tissue-specific promoters in gene therapy for the treatment of prostate cancer.

  Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW. Shirakawa T, et al. Mol Urol. 2000 Summer;4(2):73-82. doi: 10.1089/10915360050138620. Mol Urol. 2000. PMID: 12006246 Review.